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Non-adherence to tamoxifen in breast cancer survivors: A 12 month longitudinal analysis  
 
Objective: Previous research has shown that up to 50% of breast cancer survivors prescribed 
tamoxifen do not take it as recommended, which is associated with increased risk of recurrence and 
mortality. Little research has attempted to identify modifiable psychosocial factors associated with 
tamoxifen non-adherence. This study aimed to examine how tamoxifen adherence rates change over a 
year and to identify modifiable predictors of non-adherence.  
Methods: 345 breast cancer survivors who were in their first year of tamoxifen prescription were sent 
questionnaires at four points over a 12-month period. Questionnaires assessed demographic and 
clinical factors, side-effects, beliefs about the illness and medication, social support, distress and 
tamoxifen adherence. Adherence was assessed using the Medication Adherence Rating Scale. Latent 
Growth Modelling was used to identify predictors of tamoxifen non-adherence.  
Results: Reported rates of non-adherence increased over time (37-48%). Several demographic, 
clinical and psychosocial variables were associated with non-adherence. Women who were non-
adherent were more likely to be from a minority ethnic group, to have more negative medication 
beliefs and to have lower confidence in their ability to take tamoxifen.   
Conclusions: These demographic and clinical variables can be used to identify women at higher risk 
of non-adherence. The modifiable psychosocial variables can be used as the basis for psychological 
interventions to improve adherence in this population. Interventions should focus on both intentional 
and unintentional non-adherence.  
 
Keywords: adherence, illness perceptions, medication beliefs, theory of planned behaviour; 
tamoxifen, hormone therapy.  
 
 
 
 
3 
 
 
 
Introduction 
Breast cancer is the most common cancer in the UK, accounting for 15% of all new cancer 
cases and is the third most common cause of cancer-related deaths (Cancer Research UK, 2018). 
Around three quarters of breast cancers are oestrogen receptor positive and can be treated with 
hormone therapy (HT) such as tamoxifen. Prescribed to breast cancer survivors for up to ten years 
after primary treatment, tamoxifen can reduce the risk of breast cancer recurrence by 40% and 
mortality by a third (EBCTCG, 1998; EBCTCG, 2011). However, up to 50% of women take less than 
80% of the prescribed dosage, which is known as non-adherence, or stop treatment early, known as 
non-persistence, both of which are associated with increased odds of recurrence and mortality 
(Barron, Cahir, Sharp & Bennett, 2013; Brito, Portela, Leite de Vasconcellos, 2014; Hershman et al., 
2011; Hsieh, Chen, Cheung, Chang & Yang, 2014; Partridge, Wang, Winder & Avon, 2003;  van 
Herk-Sukel et al., 2010). Non-adherence can be either intentional, where the patient makes a 
deliberate decision not to take their medication, or unintentional, where they may forget to take it, or 
misunderstand the instructions.  
 
Previous research into predictors of tamoxifen non-adherence has largely focussed on clinical 
and demographic factors and has identified few consistent predictors beyond the experience of side-
effects (Cahir, Guinan, Dombrowski, Sharp & Bennett, 2015; Kadakia et al., 2016; Moon, Moss-
Morris, Hunter, Carlisle & Hughes, 2017; Pan et al., 2018). Irrespective of poor predictability, clinical 
and demographic factors have somewhat limited utility in this context as they are not amenable to 
modification through intervention, although they can identify those at increased risk of non-
adherence. Recent studies assessing modifiable psychosocial factors found that social support, 
positive medication beliefs and high self-efficacy for medication taking are associated with increased 
odds of adherence (Brett et al., 2018; Hershman et al., 2016; Huiart et al., 2012; Kimmic et al., 2015). 
However, the majority of this research is cross-sectional and longitudinal studies are scarce. 
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Furthermore, previous research often lacks a theoretical framework with clearly specified 
psychosocial mechanisms of non-adherence, which may contribute to the poor success of previous 
interventions to improve adherence (Holmes, Hughes & Morrison, 2014; Horne et al., 2005). A recent 
cross-sectional study has supported the utility of using two common social cognition models of health 
behaviour as a framework for understanding tamoxifen non-adherence (Moon, Moss-Morris, Hunter 
& Hughes, 2017b). 
 
The Common Sense Model (CSM) posits that an individual forms beliefs about their illness 
and treatment that will influence coping strategies, such as medication adherence (Leventhal et al., 
2012). These illness representations include perceptions about the identity (symptoms), causes, 
consequences, timeline, level of understanding (coherence) and amount of control a person feels over 
an illness and are continually amended in a self-regulatory process as the individual develops more 
knowledge and experience of their illness and treatment over time. The continual self-regulatory 
nature of the model lends itself to the understanding of the experience of long-term conditions which 
require ongoing management. In terms of treatment perceptions, it is hypothesised that perceptions of 
how necessary treatment is to wellbeing, and concerns patients have about the medication will affect 
adherence. These illness and treatment perceptions are associated with adherence in several conditions 
(Chen, Tsai & Choi, 2011; Horne & Weinman, 2002), including two longitudinal studies assessing 
adherence to hormonal therapy in breast cancer survivors (Fink, Gurwitz, Rakowski, Guadagnoli & 
Silliman, 2006;Corter, Broom, Porter, Harvey, & Findlay, 2018).  
 
Another set of determinants used to predict medication adherence have been drawn from the 
Theory of Planned Behaviour (TPB). The TPB was developed largely to explain preventative health 
behaviours and focuses more on performance of the desired behaviour than on the individual’s 
ongoing cognitive or emotional management of an illness and appraisal of the associated behaviours. 
The TPB is formed of the patient’s intentions to adhere, their general attitudes about medication 
taking, their beliefs about others’ attitudes towards medication taking (subjective norm), and their 
confidence in their ability to take the medication (perceived behavioural control) (Ajzen, 1991); a 
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concept which is closely aligned to self-efficacy. Despite recent criticisms with the model (Sniehotta, 
Presseau & Araujo-Soares, 2014), there is a significant body of evidence showing that constructs such 
as attitudes and perceived behavioural control explain large amounts of variance in medication 
adherence (Bane, Hughes & McElnay, 2006; Chisholm, Williamson, Lance & Mulloy, 2007;), and 
that interventions based on these constructs are able to improve medication adherence and screening 
attendance (O’Carroll, Chambers, Dennis, Sudlow & Johnston, 2013; Sheeran & Orbell, 2000). One 
study has used the TPB in HT adherence and found TPB variables could explain 66% of the variance 
in intentions to adhere, and were associated with past medication taking behaviour (Hurtado-de-
Mendoza et al., 2019). 
 
Although there are some similarities between the main constructs of these models, there are 
also important differences, particularly in how they conceptualise long-term medication management. 
The CSM’s self-regulatory process focuses on how perceptions of the illness and treatment influence 
specific coping behaviours such as the decision to take medication which are appraised and modified 
in relation to the ongoing incorporation of new knowledge and experience that the individual develops 
over time. Conversely, the TPB focuses on patients’ attitudes and confidence in performing the 
behaviour itself, alongside social influences to predict engagement in behaviour, in isolation from 
perceptions of the associated illness. These complementary concepts have been shown to be 
associated with treatment adherence in isolation (Corter et al., 2018; Fink et al., 2006; Hurtado-de-
Mendoza et al., 2019), leading researchers to suggest that using both models may increase the 
explanatory power to predict health behaviours (Holmes et al., 2014; Orbell, Hagger, Brown & Tidy, 
2006; Sivell, Edwards, Elwyn & Manstead, 2011), which has been supported by three previous 
studies which have compared and combined elements from both models to successfully explain 
attendance at cervical screening follow-up (Orbell et al., 2006) and help-seeking (Hunter, Grunfeld & 
Ramirez, 2003) and treatment adherence (Moon et al., 2017b) in breast cancer. Therefore, the current 
study operationalized measurement variables from both models alongside additional psychosocial 
factors shown to be associated with tamoxifen adherence (Moon et al., 2017a; Cahir et al., 2015) to 
predict adherence to tamoxifen in breast cancer survivors.  
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 Aims and hypotheses  
This study aimed to examine how tamoxifen adherence rates change across a one-year period, 
and to identify modifiable predictors of non-adherence, using two social cognition models of health 
behaviour as a framework. Predictors of both intentional and unintentional non-adherence were 
identified, as understanding these different behaviours is important for improving overall non-
adherence. We hypothesised that non-adherence rates would increase over time and that rates of 
unintentional non-adherence would be higher than intentional non-adherence. We also hypothesised 
that psychosocial factors such as medication beliefs will be related more to intentional non-adherence 
than to unintentional non-adherence.  
Methods 
Participants and procedure  
The study was approved by the Northampton National Research Ethics Committee (REF 
14/EM/1207). This longitudinal study was nested within a larger cross-sectional study of tamoxifen 
non-adherence (Moon et al., 2017b). Recruitment methods are described fully in the cross-sectional 
study. In short, women were recruited through National Health Service (NHS) outpatient clinics and 
online. Eligible participants were female, over the age of 18, had been diagnosed with primary breast 
cancer and had been prescribed tamoxifen. Women in their first year of treatment were included in the 
longitudinal study (n=345). Informed consent was obtained from all participants. Eligible patients 
consented to follow-up at recruitment.  
Follow-up questionnaires were sent at 3, 6 and 12 months after completion of the baseline 
survey. Questionnaires were emailed or posted, depending on the participant’s preference. If the 
questionnaire was not returned within two weeks, a reminder was sent, followed by a phone call two 
weeks later if the questionnaire was still not returned. Participants were not sent further questionnaires 
if they reported discontinuing tamoxifen at the previous time point or if they withdrew from the study.  
Measures  
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Sociodemographic and clinical factors. 
Self-reported data were collected on a range of demographic, illness and treatment related 
factors, including age, ethnicity, cancer stage and menopausal status.  
Common Sense Model (CSM) variables.  
The IPQ-BCS, a modified version of the Illness Perceptions Questionnaire, was used to 
measure illness perceptions, a key component of the CSM. The scale was modified for use in breast 
cancer survivors and has good psychometric properties (Moon, Moss-Morris, Hunter & Hughes, 
2017c). It includes ten subscales; cure, risk of recurrence, tamoxifen consequences, breast cancer 
consequences, personal control, treatment control, illness coherence, emotional representations, 
tamoxifen identity and causal attributions. Medication beliefs were assessed using the Beliefs about 
Medicines Questionnaire-Specific (BMQ-Specific). The BMQ-Specific measures both perceived 
necessity for tamoxifen and perceived concerns about this medication. Patients’ perceived cost benefit 
analysis was operationalised through a differential score calculated by subtracting necessity beliefs 
from concerns (Horne, Weinman & Hankins, 1999). A more positive necessity/concerns differential 
indicates that the patient’s necessity beliefs outweigh their concerns.  
Theory of Planned Behaviour variables.  
TPB constructs (intentions to take tamoxifen, subjective norms, attitude and perceived 
behavioural control) were assessed by three items each, based on guidance from Azjen (2002) and 
Francis et al (2004). Items were scored on a seven-point Likert scale from strongly agree to strongly 
disagree. Each subscale showed good reliability (α=0.67–0.82), except for subjective norms (α=0.52), 
however all subscales were included in order to fully test the model. 
Additional psychosocial factors.  
Perceived social support was measured with the Multidimensional Scale of Perceived Social 
Support (Zimet, Dahlem, Zimet & Farley, 1988), with higher scores indicating higher levels of 
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support. Distress was measured using the general distress scale of the Hospital Anxiety and 
Depression Scale (Zigmond & Snaith, 1983; Norton, Cosco, Doyle, Done & Sacker, 2013). The 
additional concerns subscale of the FACT-ES was used to measure the extent to which patients 
experience a range of side-effects (from ‘not at all’ to ‘very much’) (Fallowfield, Leaity, Howell, 
Benson & Cella, 1999).   
Adherence.  
Adherence was measured using the Medication Adherence Report Scale (MARS), a self-
report scale with five items scored on a five-point scale (Horne, Hankins & Jenkins, 2001). 
Participants report the extent to which they engage in adherence behaviours, scored from ‘never’ to 
‘always’. Higher scores indicate higher adherence rates. As the scale is often positively skewed 
towards high adherence, it is usually dichotomised, with participants scoring 24 or below being 
classed as non-adherent and participants scoring 25 being classed as adherent (de Vries et al., 2014; 
Timmers et al., 2016). Separate scores are generated for intentional (four items, range 4-20; ≤19 
scored as non-adherent) and unintentional non-adherence (one item, range 1-5; ≤4 scored as non-
adherent). Women who had discontinued tamoxifen were asked to provide a free text explanation as 
to why they discontinued. Women who reported discontinuing tamoxifen prematurely without the 
advice of their healthcare professional were classed as non-adherent for the analysis. 
Statistical analysis  
Statistical analyses were conducted in SPSS v21 and Mplus v7. Item level missing data within 
scales for covariates was negligible (<5%) and was replaced using mean substitution. Latent growth 
models (LGMs) were carried out to model the change in non-adherence rates over time and to identify 
factors associated with this change. Non-adherence was binary coded with adherence status being 
allowed to change from one time-point to the next. LGM assumes data is missing at random, which 
protects against bias due to differential non-response when variables relating to non-response are 
included in the analysis. Non-adherence at each of the four assessments was fixed to load onto the 
slope factor with values equal to the number of months since the baseline assessment (i.e. 0,3,6,12) 
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(see supplementary material). This allows for interpretation of co-efficients relating to time in months. 
Baseline covariates were added to the model as predictors of both the intercept and the slope.  
 
The intercept indicates baseline levels of non-adherence by representing the point at which 
the slope intercepts the vertical axis. Variables with significant effects on the slope are therefore 
associated with baseline non-adherence. The slope represents the growth or change in non-adherence 
over time. These analyses were run for total non-adherence, and separately for both intentional and 
unintentional non-adherence. Three separate models were run to test: (1) variables from the CSM, (2) 
variables from the TPB, and (3) variables from both the CSM and the TPB. In addition to the model 
variables, the following variables were also entered as theory and previous literature suggests they 
may be associated with non-adherence in this population; age, menopausal status, ethnicity, job status, 
distress, side-effects and social support (Brett et al., 2018; Lambert, Balneaves, Howard, & Gotay, 
2018; Moon et al., 2017a; Roberts et al., 2015). The variable intentions from the TPB was removed 
from the LGM analysis as it was positively skewed and showed high kurtosis. Plots were created to 
show the marginal means for covariates within the model. These plots illustrate how non-adherence 
rates change over time for +/- one standard deviation away from the mean.  
 
Results 
Response rate  
The flow of participants through the study is summarised in Figure 1. The response rate to the 
initial questionnaire was 61%. 345 participants were sent 3-month follow-up questionnaires, with a 
91% response rate (n=315). At 6 months, 332 participants were sent questionnaires, with an 86% 
response rate. At 12 months, 306 participants were sent questionnaires, with an 84% response rate. 
Thirty-nine women were not sent follow-up questionnaires as they withdrew from the study, were 
deceased or discontinued tamoxifen. The retention rate at 12 months was 75% of the original sample, 
and 84% of those who were sent all four questionnaires. Non-responders to the questionnaires across 
time points were more likely to be younger, from a minority ethnic group, pre-menopausal, less 
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adherent and to have higher distress scores and higher side-effects scores at baseline (see 
supplementary material).  
 
Participant demographics  
Participant demographics are shown in Table 1. Most participants were white British (95%), 
had a partner (76%) and were employed (71%). Age ranged from 30–90 (M =52, SD=10.3). 
Participants mostly had Stage I (41%) or Stage II breast cancer (45%) and were premenopausal at 
diagnosis (55%).  
 
Changes in adherence over time  
At baseline, 37% of women were classed as non-adherent (MARS scores ≤ 24); this increased 
to 48% at 12 months. For intentional non-adherence, 7% were classed as non-adherent at baseline 
(scores ≤19) and this rose to 10% at 12 months. For unintentional non-adherence, 35% were non-
adherent at baseline (scores ≤ 4) and 47% were non-adherent at 12 months (Figure 2). A one-way 
repeated measures ANOVA showed a significant effect of time, with adherence scores falling over the 
12 months (F(2.3, 513.4)=5.33, p=.003). Post-hoc Bonferroni tests showed significant decreases 
between baseline and 6 months (p=.037) and baseline and 12 months (p=.004). 
Discontinuation 
Only 41 women (15%) reported that they discontinued tamoxifen across the study period. The 
majority reported that they were switched to another medication or that they discontinued on their 
doctor’s orders, with only a small proportion reporting making their own choice to discontinue (n=7, 
2%).  
 
Changes in side-effects over time  
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Side-effect intensity increased significantly over time (F[2.8, 631.3]=2.37, p<.001). Post-hoc 
tests indicated significant increases between baseline (M=1.95, SD=0.59) and 12 months (M=2.15, 
SD=0.66, p<.001). 
Latent growth modelling (LGM)  
Dichotomous MARS scores (adherent/non-adherent) were used to model non-adherence in 
the LGM as the MARS scores were positively skewed. Linear and quadratic growth functions were 
both tested, with the linear growth pattern providing superior fit to the data, based on the 
Loglikelihood and BIC values (see supplementary material). The intercept represents the initial rate of 
non-adherence in the sample at baseline, and the slope represents monthly change in the rate of non-
adherence in the sample over time.  
 
Table 2 shows the results of the LGMs. The proportion of women classed as non-adherent 
increased at each time point. There was significant variance in the intercept (7.88, p=.002) but not the 
slope (0.09, p=.131).   
In the LGM with CSM variables, ethnicity was the only factor with a significant effect on the 
intercept, with women who were from minority ethnic groups having eleven times higher odds of 
non-adherence than women who were white (Table 2).  In terms of the slope of non-adherence, 
women with more positive necessity/concern differentials and who attributed more symptoms to 
tamoxifen had significantly lower odds of non-adherence over time. Marginal means plots show how 
the estimated proportions of non-adherence over the 12 months period differ for those with a positive 
necessity/concerns differential and those with a negative necessity/concerns differential (see 
supplementary material). Whilst the non-adherence rates at baseline are similar across the two groups, 
those with more negative medication beliefs have much higher rates of non-adherence over time than 
those with more positive medication beliefs.  
The same analytic approach was run to test the TPB. As with the CSM model, ethnicity was 
significantly related to the intercept, with women who were from minority ethnic groups having 
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higher odds of non-adherence at baseline (Table 2). In addition to ethnicity, PBC over medication 
taking and social support also showed a significant effect on the intercept, with higher levels of PBC 
and higher rated social support being associated with lower odds of non-adherence. The marginal 
means plots show that whilst women with higher perceived behavioural control had lower odds of 
non-adherence at baseline, the slope of non-adherence over time did not differ at different levels of 
perceived behavioural control (supplementary material).  
In the final model combining elements from both the CSM and the TPB, women who were 
from a minority ethnic group, who had lower perceived social support and lower perceived 
behavioural control over medication taking had higher odds of non-adherence at baseline. Again, 
having more positive medication beliefs was associated with lower odds of non-adherence over time, 
as was beliefs that breast cancer was cured, attributing more symptoms to tamoxifen and more 
positive attitudes towards tamoxifen.  
Intentional / unintentional non-adherence  
Additional analyses were run to determine whether the association between variables differs 
between unintentional and intentional non-adherence (Table 3). Being from a minority ethnic group, 
being younger, being employed, and perceiving lower levels of social support were associated 
uniquely with increased odds of unintentional non-adherence. Attributing symptoms to tamoxifen, 
lower coherence beliefs, and believing that psychological factors cause a recurrence were associated 
uniquely with increased odds of intentional non-adherence. Several factors were associated with both 
intentional and unintentional non-adherence; higher distress, more side-effects, less positive 
medication beliefs, lower PBC and less positive attitudes towards tamoxifen.  
Discussion 
This study is one of the first to identify modifiable psychosocial predictors of non-adherence 
to tamoxifen longitudinally. Results showed that less positive medication beliefs and lower perceived 
behavioural control (PBC) over medication taking were most consistently associated with increased 
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odds of non-adherence. Women from minority ethnic groups were also at higher odds of non-
adherence. These results provide important information on how to support women taking tamoxifen. 
  
Results showed that 37-48% of women were non-adherent, and that reported rates of non-
adherence increased significantly over time, which is consistent with previous research (Seneviratne 
et al., 2015). These results highlight the need for interventions to support women throughout their 
treatment. Women who were non-adherent at baseline were less likely to return their follow-up 
questionnaires, indicating that the levels of non-adherence reported here may be lower than the true 
incidence of non-adherence. Furthermore, self-report questionnaires are often criticised for under-
estimating non-adherence rates. Attempts were made to overcome this by setting a high cut off for 
non-adherence, as per previous recommendations (Huther et al., 2013; Stirratt et al., 2015).    
 
Interestingly, rates of discontinuation were much lower than previous estimates, at around 
15% in total, and only 2% for those who reported making their own decision to discontinue (Owusu et 
al., 2008). Previous research has been criticised for failing to consider the reasons why women 
discontinue treatment, and for classing women as non-persistent even if their clinician advised them to 
stop treatment or switched their medications (Guth, Myrick, Kilic, Eppenberger-Castori & Schmid, 
2012). Accurate rates of non-persistence, where the patient initiates the decision to stop treatment, 
may be much lower than the 40-50% previously reported. However, the lower rates of discontinuation 
in this study may be due to the self-report measurement and follow-up attrition, therefore further 
research is needed to investigate this further and identify if the predictors of non-adherence identified 
here will transfer to prediction of non-persistence.  
 
Whilst women are often told clinically that their side-effects will likely lessen over time, these 
results showed that self-reported side-effect intensity increased significantly over the twelve-month 
period. This highlights a need to develop ongoing support for women to manage their side-effects. 
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Women from minority ethnic groups were up to 26 times more likely to be non-adherent 
when controlling for other covariates. The proportion of women from minority ethnic groups was 
small, and the confidence intervals for this effect were wide; therefore caution should be taken when 
interpreting the results. However, this is an important finding, especially in light of research showing 
poorer clinical outcomes in women from minority ethnic groups compared to white women (Moller et 
al., 2016), and therefore future research is warranted to explore this further. Bivariate analyses also 
showed that women who were employed were more likely to be unintentionally non-adherent, which 
is consistent with other recent studies (Brett et al., 2018; Quinn, Fleming & Sullivan, 2016) and 
suggests that women who are working may need additional support in remembering to take their 
medication. In addition to this, women with lower perceived social support were at higher odds of 
non-adherence, and women with higher levels of distress at baseline were at increased odds of 
becoming non-adherent over time. Therefore, providing support with distress early on in treatment, 
and helping women build adequate social support, may prevent women from becoming non-adherent.  
 
However, whilst the sociodemographic factors are important for identifying who may be at 
risk of non-adherence and require more support, these factors are not amenable to change. Whilst the   
CSM and the TPB only explained a modest proportion of the variance in non-adherence, using these 
two models has helped to identify a broader range of potentially modifiable psychosocial variables, 
which may provide useful targets for interventions to improve non-adherence. In terms of the CSM, 
having less positive medication beliefs, i.e. believing that concerns outweigh the necessity of the 
medication, were associated with increased odds of non-adherence over the 12 month follow-up, even 
when controlling for other covariates. This is comparable with previous research and highlights the 
importance of medication beliefs in understanding tamoxifen adherence (Brett et al., 2018; Fink et al., 
2004). Previous studies have shown that medication beliefs can be altered through intervention, 
leading to improvements in medication adherence (Moon, Moss-Morris, Hunter, Goodliffe & Hughes, 
2019; O’Carroll et al., 2013; Petrie et al., 2012).  
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Two other CSM variables also appear relevant to future adherence interventions. High scores 
on perceptions that breast cancer was cured were associated with lower odds of non-adherence over 
time. In addition, attributing more symptoms to tamoxifen had higher odds of intentional non-
adherence at the intercept, but also lower odds of becoming non-adherent (total non-adherence) over 
time. This highlights the complex relationship between side-effects and non-adherence. Side-effects 
may be an initial driver of non-adherence, as often assumed, whereas over time symptoms resulting 
from oestrogen blocking, such as hot flushes, may be an indicator that the treatment is working 
(Cuzick et al., 2008), and may therefore be associated with lower odds of non-adherence. These 
results also highlight that whether or not symptoms are attributed to tamoxifen may be a more 
important determinant than the experience of symptoms themselves.  
 
Three other illness perceptions could also be considered for future interventions to improve 
adherence.   Perceiving severe consequences of tamoxifen, believing that psychological stress would 
cause a recurrence and lower coherence were all associated with increased odds of intentional non-
adherence, but these did not remain significant in the multivariate analyses. Although perceptions of 
personal and treatment control as measured by the modified IPQ-R were not associated with non-
adherence, perceived behavioural control (PBC) drawn from the TPB did appear to have relevance. 
PBC focuses more on the confidence in performing the medication taking behaviour itself (in this 
case, taking a daily tablet), whereas constructs of control within the IPQ-R focus on the extent to 
which the patient believes they can control their illness through this behaviour (i.e. whether taking 
tamoxifen will reduce the risk of recurrence).  
 
Variables from the TPB also contributed to explaining non-adherence. Higher perceptions of 
PBC over medication taking were associated with decreased odds of non-adherence at the intercept. 
This is supported by previous research into medication adherence showing the importance of PBC and 
provides some support for the model, helping to counter some of the criticism the model has faced 
over recent years (Chisholm et al., 2007; Sniehotta et al., 2014). In addition to PBC, attitudes towards 
tamoxifen, such as tamoxifen being beneficial or pleasant, were also a significant predictor of non-
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adherence both at baseline and over time. However, the current results do support the criticism that 
the TPB is unable to predict later behaviour, as attitudes towards tamoxifen was the only variable 
associated with non-adherence over time and may represent more perennial influences over long term 
medication taking. PBC was only related to non-adherence at baseline and had no effect on later non-
adherence. This is somewhat expected, however, as the CSM is designed to explain long-term 
adjustment to illness and treatment whereas the PBC construct of the TPB refers more specifically to 
performing the specific behaviour which is more likely to relate to adherence at the same time point 
than 12 months later. However, it was not possible to fully test the model as the variable intentions to 
take tamoxifen was strongly skewed in this population, with most women reporting strong intentions 
to adhere.  
 
 Overall, neither the CSM nor the TPB provided a perfect fit for understanding non-
adherence. There are likely additional factors affecting non-adherence which the current study is 
missing, especially when predicting later non-adherence. However, testing two complementary social 
cognition models provides a more complete analysis for explaining adherence to tamoxifen, and 
supports and extends previous studies that have found utility in assessing illness and treatment beliefs 
proposed by the CSM (Brett et al., 2018; Corter et al., 2008; Fink et al., 2004; Moon et al., 2017b) as 
well as attitudes towards and confidence in performing medication taking behaviour proposed by the 
TPB (Hurtado-de-Mendoza et al., 2019; Moon et al., 2017b) Constructs of both models remained 
important in explaining non-adherence when they were combined, suggesting that they measure 
distinct but important factors. Furthermore, there were hypothesised differences between the 
psychosocial factors with the CSM being related to intentional but not unintentional non-adherence. 
This has important implications for future interventions.   
Clinical implications  
Taken together, these results highlight women who may be at higher risk of non-adherence, 
such as those who are younger, from minority ethnic groups, who are employed and who have higher 
levels of distress. Clinicians can identify these women and give them additional support with their 
17 
 
medication taking and with managing distress. In addition to this, the results highlight ways in which 
adherence could be improved through intervention, by modifying the psychosocial variables identified 
in this study. Previous interventions based on modifying medication beliefs and increasing PBC have 
shown success at improving adherence rates (Moon et al., 2019; O’Carroll et al., 2013; Petrie, Perry, 
Broadbent & Weinman, 2012). Results showed that demographic factors, such as ethnicity, age and 
employment status were associated with unintentional non-adherence, whereas psychological factors 
such as perceptions around risk of recurrence tended to be associated more with intentional non-
adherence. These results have important implications for understanding how to intervene and improve 
non-adherence. Finally, the results showed that instead of decreasing over time, the perceived impact 
of self-reported side-effects increased over the first 24 months. This is especially important 
considering qualitative research showing that some women feel dismissed by healthcare professionals 
and feel un-validated in their experience of side-effects (Moon, Moss-Morris, Hunter & Hughes, 
2017d). Supporting women to manage their side-effects, as well as re-evaluating their weight in the 
decisional balance to minimise side-effect related concerns presents a potential target for intervention  
Study limitations  
Whilst retention rates were relatively high, significant differences were seen between 
responders and non-responders. Women who did not respond were more likely to be younger, from a 
minority ethnic group and to be more non-adherent at baseline, which is a common limitation with 
adherence research. There was little ethnic diversity in the sample, so future research should be 
conducted with a more representative sample in order to further explore the relationship between 
ethnicity and non-adherence. The research only focused on women prescribed tamoxifen, as 
tamoxifen was more widely prescribed when the study was designed. Future research could extend 
this to women prescribed aromatase inhibitors. Finally, there are criticisms associated with the use of 
self-report measures of non-adherence such as the MARS, which are known to over-estimate 
adherence rates. However, the MARS is designed to overcome some of these limitations by using 
language which normalises non-adherence. Furthermore, in order to counter the over-estimation of 
adherence, a high cut off point was used to dichotomise non-adherence, based on previous 
18 
 
recommendations (Huther et al., 2013; Stirratt et al., 2015). Whilst the MARS has shown good 
concordance with objective measures (O’Carroll et al., 2013), it is unclear if the levels of non-
adherence reported here are associated with poor clinical outcomes. Whilst it was not possible in this 
study, future research could overcome these limitations by triangulating from multiple sources, such 
as pharmacy records, pill counts, or electronic monitoring.  
To conclude, results show that reported rates of non-adherence increase significantly over a 
one-year follow-up period. Unintentional non-adherence was reported more frequently than 
intentional non-adherence and was associated with some unique predictors. A key sociodemographic 
predictor of non-adherence was ethnicity, with women from minority ethnic groups being at higher 
odds of non-adherence. The research has identified several potentially modifiable targets, such as 
medication beliefs and perceived behavioural control over medication taking, which can form the 
basis of interventions to improve non-adherence in this population. 
19 
 
Acknowledgements 
 We are grateful to all the women who took part in the study. We would also like to thank all the sites 
who recruited to the study and Breast Cancer Care and Macmillan Cancer Support for assisting us 
with online advertisements. This study was funded by Breast Cancer Now, grant number 
2013NovPhD201.  
Conflict of interest 
The authors declare that they have no conflict of interest. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
20 
 
References 
Ajzen, I.(1991). The theory of planned behavior. Organizational Behavior and Human Decision 
Processes 50, 179-211. 
Azjen, I. (2002). Constructing a TPB questionnaire: Conceptual and methodological considerations. 
2002. Retrieved from: 
http://chuang.epage.au.edu.tw/ezfiles/168/1168/attach/20/pta_41176_7688352_57138.pdf 
Aujla, N., Walker, M., Sprigg, N., Abrams, K., Massey, A., & Vedhara, K (2016). Can illness beliefs, 
from the common-sense model, prospectively predict adherence to self-management behaviours? A 
systematic review and meta-analysis. Psychology & Health, 31, 931-58.  doi: 
10.1080/08870446.2016.1153640. 
 
Bane, C., Hughe, C.M., & McElnay, J.C. (2006). Determinants of medication adherence in 
hypertensive patients: an application of self-efficacy and the Theory of Planned Behaviour. 
International Journal of Pharmacy Practice, 14, 197-204. doi: 10.1211/ijpp.14.3.0006 
Barron, T.I., Cahir, C., Sharp, L., & Bennett, K. (2013). A nested case-control study of adjuvant 
hormonal therapy persistence and compliance, and early breast cancer recurrence in women with 
stage I-III breast cancer. British Journal of Cancer, 109. 1513-21. doi: 10.1038/bjc.2013.518 
Brandes, K., & Mullan, B.(2014). Can the common-sense model predict adherence in chronically ill 
patients? A meta-analysis. Health Psychology Review, 8, 129-53. doi: 
10.1080/17437199.2013.820986 
Brett, J., Fenlon, D., Boulton, M., Hulbert-Williams, N.J., Walter, F., Donnelly, P. et al. (2018). 
Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy 
following breast cancer. European Journal of Cancer Care, 27, 1.doi: doi.org/10.1111/ecc.12601 
Brito, C., Portela, M.C., & Leite de Vasconcellos, M.T. (2014). Factors associated to persistence with 
hormonal therapy in women with breast cancer. Revista de Saude Publica, 48, 284-95.  
Cahir, C., Guinan, E., Dombrowski, S.U., Sharp, L., & Bennett, K. (2015). Identifying the 
determinants of adjuvant hormonal therapy medication taking behaviour in women with stages I–III 
breast cancer: a systematic review and meta-analysis. Patient Education and Counselling. Advanced 
Online Publication. doi: 10.1016/j.pec.2015.05.013  
Cancer Research UK. (2018, March 15). Breast Cancer Statistics. Retrieved from: 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-
cancer#heading-Two 
Chen, S.L., Tsai, J.C., Chou, K.R. (2011). Illness perceptions and adherence to therapeutic regimens 
among patients with hypertension: a structural modeling approach. International Journal of Nursing 
Studies, 48, 235-45. doi: 10.1016/j.ijnurstu.2010.07.005 
Chisholm, M.A., Williamson, G.M., Lance, C.E., & Mulloy, L.L. (2007). Predicting adherence to 
immunosuppressant therapy: a prospective analysis of the theory of planned behaviour. Nephrology 
Dialysis Transplantation, 22, 2339-48. doi: 10.1093/ndt/gfm149 
21 
 
Corter, A.L., Broom, R., Porter, D., Harvey, V., Findlay, M. (2018). Predicting nonadherence to 
adjuvant endocrine therapy in women with early stage breast cancer. Psycho-oncology, 27, 2096-
2103. doi: 10.1002/pon.5771 
Cuzick, J., Sestak, I., Cella, D., Fallowfield, L., on behalf of ATAC Trialists’ Group. (2008). 
Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective 
analysis of the ATAC trial. The Lancet Oncology, 9, 1143-1148. doi: 10.1016/S1470-2045(08)70259-
6 
de Vries, S.T., Keers, J.C., Visser, R., de Zeeuw, D., Haaijer-Ruskamp, F.M., Voorham, J. et al. 
(2014). Medication beliefs, treatment complexity, and non-adherence to different drug classes in 
patients with type 2 diabetes. Journal of Psychosomatic Research, 76, 134-8. doi: 
10.1016/j.jpsychores.2013.11.003 
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (1998). Tamoxifen for early breast 
cancer: an overview of the randomised trials. Lancet, 351, 1451-67.  
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).(2011). Relevance of breast cancer 
hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis 
of randomised trials. Lancet, 378, 771-84. doi: 10.1016/S0140-6736 
Fallowfield, L.J., Leaity, S.K., Howell, A., Benson, S., & Cella, D. (1999). Assessment of quality of 
life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom 
subscale for the FACT-B. Breast Cancer Research and Treatment, 55, 189-99.  
Fink, A.K., Gurwitz, J., Rakowski, W., Guadagnoli, E., & Silliman, R.A. (2004). Patient beliefs and 
tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer. Journal of 
Clinical Oncology, 22, 3309-15. doi: 10.1200/JCO.2004.11.064 
Francis, J.J., Eccles, M.P., Johnston, M., Walker, A., Grimshaw, J., Foy, R. et al. (2004). Constructing 
questionnaires based on the theory of planned behaviour. A manual for health services researchers. 
Centre for Health Services Research: Newcastle upon Tyne, UK.  
Grunfeld, E.A., Hunter, M.S., Sikka, P., & Mittal, S. (2005). Adherence beliefs among breast cancer 
patients taking tamoxifen. Patient Education and Counselling, 59, 97-102. doi: 
10.1016/j.pec.2004.10.005 
Guth, U., Myrick, M.E., Kilic, N., Eppenberger-Castori, S.,  Schmid, S.M. (2012). Compliance and 
persistence of endocrine adjuvant breast cancer therapy. Breast Cancer Research and Treatment, 131, 
491-9. doi: 10.1007/s10549-011-1801-y. 
Hershman, D.L., Kushi, L.H., Hillyer, G.C., Coromilas, E., Buono, D., Lamerato, L. et al. (2016). 
Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with 
breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Research and 
Treatment,157, 133-43. doi: 10.1007/s10549-016-3788-x 
Hershman, D.L., Shao, T., Kushi, L.H., Buono, D., Tsai, W.Y., Fehrenbacher, L., et al. (2011). Early 
discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased 
mortality in women with breast cancer. Breast Cancer Research and Treatment, 126, 529-37. doi: 
10.1007/s10549-010-1132-4  
22 
 
Holmes, E.A., Hughes, D.A., & Morrison, V.L. (2014). Predicting adherence to medications using 
health psychology theories: a systematic review of 20 years of empirical research. Value in Health, 
17, 863-76. doi:10.1016/j.jval.2014.08.2671 
Horne, R., Hankins, M., & Jenkins, R. (2001). The Satisfaction with Information about Medicines 
Scale (SIMS): a new measurement tool for audit and research. Quality in Health Care, 10, 135-40. 
doi: 10.1136/qhc.0100135 
Horne, R., & Weinman, J. (2002). Self-regulation and Self-management in Asthma: Exploring The 
Role of Illness Perceptions and Treatment Beliefs in Explaining Non-adherence to Preventer 
Medication. Psychology & Health, 17, 17-32. doi: 10.1080/08870440290001502 
Horne, R., Weinman, J., Barber, N., Elliott, R., Morgan, M., Cribb, A. et al. (2005). Concordance, 
adherence and compliance in medicine taking. National Co-ordinating Centre for NHS Service 
Delivery and Organisation: London. 
Horne, R., Weinman, J., & Hankins, M. (1999). The beliefs about medicines questionnaire: The 
development and evaluation of a new method for assessing the cognitive representation of medication. 
Psychology & Health, 14, 1-24. doi: 10.1080/08870449908407311 
Hsieh, K-P., Chen, L-C., Cheung, K-L., Chang, C-S., & Yang, Y-H. (2014). Interruption and Non-
Adherence to Long-Term Adjuvant Hormone Therapy Is Associated with Adverse Survival Outcome 
of Breast Cancer Women - An Asian Population-Based Study. Plos One 9. doi: 
10.1371/journal.pone.0087027.t001 
Huiart, L., Bouhnik, A.D., Rey, D., Tarpin, C., Cluze, C., Bendiane, M.K. et al. (2012). Early 
discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the 
way it is prescribed? European Journal of Cancer, 48, 1939-46. doi: 10.1016/j.ejca.2012.03.004 
Hunter, M.S., Grunfeld, E.A., & Ramirez, A.J. (2003). Help‐seeking intentions for breast‐cancer 
symptoms: A comparison of the self‐regulation model and the theory of planned behaviour. British 
Journal of Health Psychology, 8, 319-33. doi: 135910703322370888 
 
behaviour. British Journal of Health Psychology, 8, 319-333. doi: 135910703322370888 Hurtado-de-
Mendoza, A., Cabling, M.L., Lobo, T., Dash, C., & Sheppard, V.B. (2018). Behavioural Interventions 
to Enhance Adherene to Hormone Therapy in Breast Cancer Survivors: A Systematic Literature 
Review. Clinical Breast Cancer, 16, 247-255. doi: 10.1016/j.clbc.2016.03.006  
Hurtado-de-Mendoza, A., Carrera, P., Parrott, W.G., Gomez-Trillos, S., Perera, R.A., & Sheppard, 
V.B. (2018). Applying the theory of planned behaviour to examine adjuvant endocrine therapy 
adherene intentions. Psycho-oncology, 28, 187-194. doi: 10.1002/pon.4931 
Hüther, J., von Wolff, A., Stange, D., Härter, M., Baehr, M., Dartsch, D.C. et al. (2013). Incomplete 
medication adherence of chronically ill patients in German primary care. Patient Preference and 
Adherence, 7,  237-44. doi: 10.2147/PPA.S38373 
Kadakia, K.C., Snyder, C.F., Kidwell, K.M., Seewald, N.J., Flockhart, D.A., Skaar, T.C. et al. (2016). 
Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated 
Postmenopausal Women With Early Stage Breast Cancer. The Oncologist, 21, 539-46. doi 
10.1634/theoncologist.2015-0349 
23 
 
Kimmick, G., Edmond, S.N., Bosworth, H.B., Peppercorn, J., Marcom, P.K., Blackwell, K. et al. 
(2015). Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy. The 
Breast, 24, 630-6. doi: 10.1016/j.breast.2015.06.01 
Lambert, L.K., Balneaves, L.G., Howard, A.F., & Gotay, C.C. (2018). Patient-reported factors 
associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review. 
Breast Cancer Research & Treatment, 167, 615 – 633. doi: 10.1007/s10549-017-4561-5 
Leventhal, H., Bodnar-Deren, S., Breland, J.Y., Hash-Converse, J., Phillips, L.A., & Leventhal, E.A. 
et al. (2012). Modeling Health and Illness Behaviour: The approach of the Commonsense Model. In 
A.B. Baum, T.A. Revenson, & J. Singer J (Eds.), Handbook of Health Psychology 2nd Edition (pp 3-
36). New York: Psychology Press, Taylor & Francis Group. 
Lin, C-Y., Updegraff, J.A., & Pakpour, A.H. (2016). The relationship between the theory of planned 
behavior and medication adherence in patients with epilepsy. Epilepsy & Behavior, 61, 231-6. doi: 
10.1016/j.yebeh.2016.05.030 
Møller, H., Henson, K., Lüchtenborg, M., Broggio, J., Charman, J., Coupland, V. H., et al. (2016). 
Short-term breast cancer survival in relation to ethnicity, stage, grade and receptor status: National 
cohort study in England. British Journal of Cancer, 115, 1408-1415. doi: 10.1038/bjc.2016.335 
 
Moon, Z., Moss-Morris, R., Hunter, M.S., Carlisle, S., & Hughes, L.D. (2017a). Barriers and 
facilitators of adjuvant hormone therapy adherence and persistence in women with breast cancer: a 
systematic review. Patient Preference and Adherence, 11, 305-22. doi: 10.2147/ppa.s126651   
Moon, Z., Moss-Morris, R., Hunter, M.S., Goodliffe, S., & Hughes, L.D. (2019) Acceptability and 
feasibility of a self-management intervention for women prescribed tamoxifen. Health Eduction 
Journal. In Press.  
Moon, Z., Moss-Morris, R., Hunter, M.S., & Hughes, L.D. (2017b). More than just side-effects: The 
role of clinical and psychosocial factors in non-adherence to tamoxifen. British Journal of Health 
Psychology, 22, 998-1018. doi: 10.1111/bjhp.12274 
Moon, Z,, Moss-Morris, R., Hunter, M.S., & Hughes, L.D. (2017c). Measuring illness representations 
in breast cancer survivors (BCS) prescribed tamoxifen: Modification and validation of the Revised 
Illness Perceptions Questionnaire (IPQ-BCS). Psychology & Health, 32, 439-58. doi: 
10.1080/08870446.2016.1275629 
Moon, Z., Moss-Morris, R., Hunter, M.S., & Hughes, L.D. (2017d). Understanding tamoxifen 
adherence in women with breast cancer: A qualitative study. Brtish Journal of Health Psychology, 22, 
978-97. doi: 10.1111/bjhp.12266 
Norton, S., Cosco, T., Doyle, F., Done, J., & Sacker, A. (2013). The Hospital Anxiety and Depression 
Scale: A meta confirmatory factor analysis. Journal of Psychosomatic Research, 74, 74-81. doi: 
10.1016/j.jpsychores.2012.10.010 
O'Carroll, R.E., Chambers, J.A., Dennis, M., Sudlow, C., & Johnston, M. (2013). Improving 
adherence to medication in stroke survivors: a pilot randomised controlled trial. Annals of 
Behavioural Medicine, 46, 358-68.  
24 
 
Orbell, S., Hagger, M., Brown, V., & Tidy, J. (2006). Comparing two theories of health behavior: a 
prospective study of noncompletion of treatment following cervical cancer screening. Health 
Psychology, 25, 604-15. doi: 10.1037/0278-6133.25.5.604 
Owusu, C., Buist, D.S.M., Field, T.S., Lash, T.L., Thwin, S.S., Geiger, A.M. et al. (2008). Predictors 
of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. 
Journal of Clinical Oncology, 26, 549-5. doi: 10.1200/JCO.2006.10.1022 
Pan, Y., Heisig, S.R., von Blanckenburg, P., Albert, U-S., Hadji, P., Rief, W. et al. (2018). Facilitating 
adherence to endocrine therapy in breast cancer: stability and predictive power of treatment 
expectations in a 2-year prospective study. Breast Cancer Research and Treatment, 168, 667-77. doi: 
10.1007/s10549-017-4637-2 
Partridge, A.H., Wang, P.S., Winer, E.P.,& Avorn, J. (2003). Nonadherence to adjuvant tamoxifen 
therapy in women with primary breast cancer. Journal of Clinical Oncology, 21, 602-6. doi: 
10.1200/JCO.2003.07.071  
Petrie, K.J., Perry, K., Broadbent, E., & Weinman, J. (2012). A text message programme designed to 
modify patients’ illness and treatment beliefs improves self-reported adherence to asthma preventer 
medication. Brtish Journal of Health Psychology, 17, 74-84. doi: 10.1111/j.2044-8287.2011.02033.x 
Quinn, E., Fleming, C., & O’Sullivan, M. (2016). Endocrine therapy adherence: a cross-sectional 
study of factors affecting adherence and discontinuation of therapy. Irish Journal of Medical Science, 
185, 383-92. doi: 10.1007/s11845-015-1307-4 
Roberts, M.C., Wheeler, S.B., & Reeder-Hayes, K. (2015). Racial/Ethnic and Socioeconomic 
Disparities in Endocrine Therapy Adherence in Breast Cancer: A Systematic Review. Americal 
Journal of Public Health, 105, e4-e15. doi: 10.2105/AJPH.2014.302490 
Seneviratne, S., Campbell, I., Scott, N., Kuper-Hommel, M., Kim, B., Pillai, A., et al. (2015). 
Adherence to adjuvant endocrine therapy: is it a factor for ethnic differences in breast cancer 
outcomes in New Zealand? Breast, 24, 62-7. doi: 10.1016/j.breast.2014.11.011 
Sivell, S., Edwards, A., Elwyn, G., & Manstead, A.S. (2011). Understanding surgery choices for 
breast cancer: how might the Theory of Planned Behaviour and the Common Sense Model contribute 
to decision support interventions? Health Expectations, 14, 6-19. doi: 10.1111/j.1369-
7625.2009.00558.x 
Sheeran, P,, & Orbell, S. (2000). Using implementation intentions to increase attendance for cervical 
cancer screening. Health Psychology, 19, 283. doi: 10.1007/s12160-013-9515-5 
Sniehotta, F.F., Presseau, J., & Araújo-Soares, V. (2014). Time to retire the theory of planned 
behaviour. Health Psychology Review, 8, 1-7. doi: 10.1080/17437199.2013.869710 
Stirratt, M.J., Dunbar-Jacob, J., Crane, H.M., Simoni, J.M., Czajkowski, S., Hilliard, M.E. et al. 
(2015). Self-report measures of medication adherence behavior: recommendations on optimal use. 
Translational Behavioral Medicine, 5, 470-82. doi: 10.1007/s13142-015-0315-2 
Timmers, L., Boons, C.C.L.M., Mangnus, D., Van de Ven, P.M., Van den Berg, P.H., Beeker, A. et 
al. (2016). Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. 
Frontiers in Pharmacology, 7, 310. doi: 10.3389/fphar.2016.00310 
25 
 
van Herk-Sukel, M.P., van de Poll-Franse, L.V., Voogd, A.C., Nieuwenhuijzen, G.A., Coebergh, 
J.W., & Herings, R.M. (2010). Half of breast cancer patients discontinue tamoxifen and any endocrine 
treatment before the end of the recommended treatment period of 5 years: a population-based 
analysis. Breast Cancer Research and Treatment, 122, 843-51. doi: 10.1007/s10549-009-0724-3 
Zigmond, A.S., & Snaith, R.P. (1983). The HospitalAnxiety and Depression Scale. Acta Psychiatria 
Scandinavica, 67, 361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x 
Zimet, G.D., Dahlem, N.W., Zimet, S.G., & Farley, G.K. (1988). The Multidimensional Scale of 
Perceived Social Support. Journal of Personality Assessessment, 52, 30-41. doi: 
10.1207/s15327752jpa5201_2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
26 
 
Table 1 
Demographic and clinical characteristics of participants 
  N (%) 
Age  Range 30-90, M=51.7 (SD=10.3) 
Age left full time education Range 14-33, M=18, (SD=2.9) 
Ethnicity   
    White 325 (95%) 
     Other  19 (5%) 
Job Status   
    Employed 235 (71%) 
    Not employed 98 (29%) 
Relationship status   
    With partner 261 (76%) 
    Not with partner 82 (24%) 
Menopausal status at diagnosis   
    Premenopausal  175 (55%) 
    Menopausal / Post- Menopausal 144 (45%) 
Months since prescribed tamoxifen   
    < 1 month  28 (8%) 
   1-3 months  70 (20%) 
   3-6 months  93 (27%) 
   6-8 months  47 (14%) 
   8-12 months  100 (29%) 
Stage at diagnosis    
   Stage I  138 (41%) 
   Stage II 153 (45%) 
   Stage III 39 (11%) 
   Unsure 11 (3%) 
Previous treatment    
   Chemotherapy  163 (47%) 
   Radiotherapy 256 (74%) 
   Lumpectomy  219 (64%) 
   Single mastectomy  115 (33%) 
   Double mastectomy  16 (5%) 
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Table 2. Results of Latent Growth Models predicting non-adherence 
 Common Sense Model  Theory of Planned Behaviour Combined model 
  
Effect on initial 
non-adherence  
 
OR (95% CI)  
Effect on slope 
Effect on 
initial non-
adherence  
 
OR (95% 
CI) 
Effect on slope 
Effect on initial 
non-adherence 
 
 OR (95% CI) 
Effect on 
slope 
Model slope  0.221 0.619  0.704 
Ethnicity (black/minority 
ethnic groups) 
11.69* 
 (1.29 - 110.61) 
-0.01  
(-0.35 – 0.32) 
26.39**  
(2.12 – 328.3) 
-0.10  
(-0.47 – 0.26) 
37.4** 
(2.77 – 504.7) 
-0.15  
(-0.52 – 0.22) 
Job (employed)  
3.22 
 (0.95 – 10.84) 
0.18  
(-0.01 – 0.36) 
2.58  
(0.77 – 8.65) 
0.09  
(-0.09 – 0.28) 
3.26 
 (0.91 – 11.72) 
0.14  
(-0.06 – 0.33) 
Menopausal status (post-
menopausal) 
1.37  
(0.38 – 4.98) 
-0.13  
(-0.30 – 0.04) 
1.70  
(0.48 – 5.98) 
-0.12  
(-0.30 – 0.06) 
2.05 
 (0.94 – 7.93) 
-0.20*  
(-0.39 - -0.01) 
Age 
0.96  
(0.90 – 1.03) 
0.00 
 (-0.01-0.01) 
0.97  
(0.89 – 1.03) 
-0.00  
(-0.01 – 0.01) 
0.97  
(0.90 – 1.04) 
0.00  
(-0.01 – 0.01) 
Distress 
1.01 
 (0.91 – 1.12) 
0.02  
(-0.00 – 0.03) 
0.98  
(0.89 – 1.07) 
0.01  
(0.00 – 0.03) 
0.99  
(0.88 – 1.10) 
0.01  
(0.00 – 0.03) 
Social support  
0.73  
(0.48 – 1.11) 
-0.01  
(-0.07 – 0.05) 
0.65* 
(0.43 – 0.97) 
-0.02 
 (-0.08 – 0.05) 
0.61* 
(0.39 – 0.96) 
-0.01  
(-0.07 – 0.06) 
Side effect intensity 
0.97 
 (0.91 – 1.04) 
0.00 
 (-0.01 – 0.01) 
0.98  
(0.93 -1.03) 
0.00  
(-0.01 – 0.01) 
0.96  
(0.90 – 1.03) 
0.00  
(-0.01 – 0.01) 
Necessity-concerns 
differential 
0.93  
(0.83 – 1.04) 
-0.03** 
 (-0.05 - -0.01)  
  
0.98  
(0.88 – 1.12) 
-0.02*  
(-0.04 - 0.00)  
Risk of recurrence 
0.95  
(0.78 – 1.14) 
-0.01  
(-0.04-0.01) 
  
0.95  
(0.78 – 1.16)  
-0.02  
(-0.05 – 0.01) 
Breast cancer consequences 
0.97  
(0.81 – 1.16)  
0.01  
(-0.02 – 0.03) 
  
0.93  
(0.77 – 1.12) 
0.02  
(-0.01 – 0.04) 
Personal control 
0.94 
 (0.45 – 1.18) 
0.02  
(-0.01 – 0.05) 
  
0.98  
(0.77 – 1.24) 
0.02  
(-0.01 – 0.05)  
Treatment control 
1.30  
(0.94 – 1.80) 
0.01 
 (-0.04 – 0.05) 
  
1.22  
(0.87 – 1.71) 
0.01  
(-0.04 – 0.06) 
Coherence 
0.94 
 (0.77 – 1.15)  
0.01 
 (-0.03 – 0.03) 
  
1.03 
 (0.83 – 1.28)  
0.00  
(-0.03 – 0.04) 
Emotional representations 
0.93 
 (0.80 - 1.09) 
-0.00 
 (-0.02 – 0.02) 
  
0.96 
 (0.82 – 1.13)  
-0.00  
(-0.03 – 0.02)  
Cure 
0.86 
 (0.72 – 1.04) 
-0.02 
 (-0.05 – 0.00) 
  
0.89  
(0.73 – 1.08)  
-0.03*  
(-0.06 – 0.00) 
Tamoxifen consequences 
1.13  
(0.95 – 1.34) 
0.02  
(-0.01 – 0.05) 
  
1.07  
(0.89 – 1.29)  
0.02  
(-0.01 – 0.05) 
Causal beliefs: health 
behaviour 
1.04  
(0.46 – 2.40) 
-0.05 
 (-0.17 – 0.08) 
  
0.80  
(0.34 – 1.90) 
-0.02  
(-0.16 – 0.10) 
Causal beliefs: psychological 
stress 
1.25 
 (0.67 – 2.32) 
-0.06  
(-0.14 – 0.02) 
  
1.53 
 (0.79 – 2.94)  
-0.08 (-0.18 – 
0.01) 
Symptoms attributed to 
tamoxifen (identity) 
1.04  
(0.90 – 2.32) 
-0.03*  
(-0.05- -0.00) 
  
1.06 
 (0.91 – 1.23)  
-0.03*  
(-0.05- 0.00)  
Attitude towards tamoxifen    
0.96  
(0.90 – 1.03) 
-0.01  
(-0.02 – 0.00) 
0.91 
 (0.98 – 1.05) 
-0.01*  
(-0.02 – 0.00)  
Subjective Norm   
1.25  
(0.75 – 2.06) 
0.01 
 (-0.07 – 0.08) 
1.31 
 (0.76 – 2.25)  
0.01 
 (-0.07 – 0.09)  
Perceived Behavioural 
Control 
  
0.37*** 
(0.21 – 0.64) 
-0.05  
(-0.15 – 0.05) 
0.34***  
(0.19 – 0.62)  
-0.02  
(-0.11 – 0.07)  
Note. *p<.05, **p<.01, ***p<.001. All covariates were measured at baseline. 
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Table 3. Results of Latent Growth Models predicting unintentional and intentional non-adherence 
 Intentional non-adherence Unintentional non-adherence 
  
Effect on 
initial non-
adherence  
 
OR 
95% CI 
Change in 
non-
adherence 
(slope) 
Effect on 
slope 
Effect on 
initial non-
adherence  
 
OR 
95% CI 
Change in 
non-
adherence 
(slope) 
Effect on 
slope 
Ethnicity 
(black/minority 
ethnic groups) 
0.99  
(0.92 – 1.06) 
0.22 
-0.00  
(-0.01 – 0.01) 
11.65* 
(1.49 – 91.10) 
0.11 
0.02 
(-0.27 – 0.31) 
Job (employed)  
1.26  
(0.26 – 6.18) 
0.16 
-0.04  
(-0.20 – 0.12)  
3.79* 
(1.30 – 11.06) 
0.04 
0.09 
(-0.05 -0.24) 
Menopausal status 
(post-menopausal) 
0.98  
(0.92 -1.06) 
0.24 
0.00  
(-0.01 – 0.01) 
0.47  
(0.16 – 1.34) 
0.16 
-0.10 
(-0.23 – 0.03)  
Age 
0.99  
(0.92 – 1.06) 
0.02 
0.00 
(-0.01 – 0.01) 
0.95* 
(0.90 – 0.99) 
0.37 
-0.01 
(-0.01 – 0.00) 
Distress 
1.15** 
(1.05 – 1.28) 
0.09 
0.00 
(-0.01 – 0.02) 
1.04  
(0.98 – 1.11) 
-0.01 
0.01** 
(0.00 – 0.02) 
Social support 
0.64 
(0.37 – 1.08) 
0.10 
0.00 
(-0.07 – 0.07) 
0.66* 
(0.45 – 0.96) 
0.24 
-0.02 
(-0.07 -0.03) 
Side effect 
intensity 
1.08* 
(1.02 – 1.15) 
0.14 
0.00 
(-0.01 – 0.01) 
1.02 
(0.98 – 1.06) 
-0.01 
0.01* 
(0.00 – 0.01) 
Necessity-
concerns 
differential 
0.76** 
(0.65 – 0.87) 
0.10 
0.00 
(-0.02 – 0.02)  
0.92 
(0.84 – 1.01) 
 
0.15 
-0.02* 
(-0.03 – 0.00) 
Risk of recurrence 
0.98 
 (0.78 – 1.22) 
0.14 
0.00 
(-0.03 – 0.02) 
1.03 
(0.89 – 1.20) 
0.07 
0.01 
(-0.01 – 0.02) 
Breast cancer 
consequences 
1.23  
(0.98 – 1.55) 
0.08 
0.00 
(-0.02 – 0.03) 
1.10 
(0.96 – 1.27) 
-0.07 
0.02 
(0.00 – 0.03) 
Personal control 
0.97 
(0.77 – 1.23) 
0.25 
-0.01 
(-0.03 – 0.02) 
1.00 
(0.85 – 1.18) 
0.08 
0.00 
(-0.02 – 0.02) 
Treatment control 
0.76 
(0.54 – 1.05) 
0.13 
0.00 
(-0.04 – 0.04) 
1.01 
(0.82 – 1.24) 
0.36 
-0.02 
(-0.04 – 0.01) 
Coherence 
0.78* 
(0.62 – 0.99) 
-0.14 
0.02 
(-0.01 – 0.04) 
0.88 
(0.74 – 1.04) 
0.17 
0.00 
(-0.03 – 0.02) 
Cure  
1.04 
(0.81 – 1.33) 
0.23 
-0.01 
(-0.03 – 0.02) 
0.91 
(0.77 – 1.06) 
0.31 
-0.01 
(-0.03 – 0.01) 
Emotional 
representations 
1.04  
(0.87 – 1.25) 
0.09 
0.00 
(-0.02 – 0.02)  
1.05 
(0.93 – 1.18) 
0.00 
0.01 
(-0.01 – 0.02) 
Tamoxifen 
consequences 
1.33** 
(1.09 – 1.64) 
0.08 
0.00 
(-0.02 – 0.03)  
1.09 
(0.96 – 1.25) 
-0.07 
0.02* 
(0.00 – 0.04) 
Causal beliefs: 
health behaviour 
1.00 
(0.37 – 2.68) 
0.43 
-0.09 
(-0.20 – 0.02) 
1.50 
(0.78 – 2.90) 
0.16 
-0.01 
(-0.10 – 0.07) 
Causal beliefs: 
psychological 
stress 
2.25* 
(1.03 – 4.92) 
0.30 
-0.06 
(-0.14– 0.02)  
1.37 
(0.83 – 2.27) 
0.14 
-0.01 
(-0.07 – 0.05) 
Symptoms 
attributed to 
tamoxifen 
(identity) 
1.20* 
(1.03 -1.40) 
0.14 
-0.01 
(-0.02 – 0.01) 
1.05 
(0.95 – 1.17) 
0.09 
0.01 
(-0.01 – 0.02) 
Attitude towards 
tamoxifen  
0.87**  
(0.79 – 0.96) 
-0.17 
0.01 
 (-0.01 – 0.02) 
0.94* 
(0.89 – 1.00) 
0.53 -0.01 
(-0.02 – 0.00)  
Subjective Norm 
0.73 
(0.40 – 1.32) 
0.22 
-0.02 
(-0.08 - 0.05) 
0.67 
(0.44 – 1.02) 
0.34 -0.04 
(-0.09 – 0.02) 
Perceived 
Behavioural 
Control 
0.30*** 
(0.16 – 0.56) 
0.05 
-0.01 
(-0.07 – 0.09) 
0.52** 
(0.34 – 0.78) 
0.43 -0.05 
(-0.11 – 0.01) 
Note. *p<.05, **p<.01, ***p<.001. All covariates were measured at baseline. 
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Figure 1. Participant retention 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligible participants (within first year of 
tamoxifen prescription) sent 3 month 
questionnaires 
n=345 
 
Returned 3 month questionnaire 
n = 315  
Did not return 3 month questionnaire 
n = 30  
(patient deceased n=1, lost to follow up 
n=29) 
 
Sent 6 month questionnaires  
n=332 
Returned 6 month questionnaire 
n = 286 
Did not return 6 month questionnaire 
n = 46  
(deceased n=1, lost to follow up n=37, 
discontinued tamoxifen n=7, withdrew n=1) 
 
Sent 12 month questionnaires  
n=306 
Returned 12 month questionnaire 
n = 258 
Did not return 12 month questionnaire 
n = 48  
(deceased n=1, lost to follow up n=43, 
discontinued tamoxifen n=1, withdrew n=1) 
 
Completed baseline questionnaires as part of 
larger cross-sectional study  
n=777 
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Figure 2. Percentage of women classed as non-adherent at each time point. 
 
 
 
Note. Women can be classed as both intentionally non-adherent and unintentionally non-adherent.  
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